InicioIMGN • BMV
add
ImmunoGen Ord Shs
Cierre anterior
268,50 $
Intervalo anual
268,50 $ - 268,50 $
Cap. bursátil
8724,23 M USD
Relación precio-beneficio
-
Rentabilidad por dividendo
-
Noticias sobre los mercados
Datos financieros
Estado de resultados
Ingresos
Ingresos netos
| (USD) | sept 2023info | Cambio interanual |
|---|---|---|
Ingresos | 113,42 M | 637,72 % |
Gastos operativos | 37,74 M | 12,26 % |
Ingresos netos | 30,75 M | 139,54 % |
Margen de beneficio neto | 27,11 | 105,36 % |
Beneficios por acción | 0,10 | 132,26 % |
EBITDA | 26,38 M | 134,26 % |
Tipo impositivo efectivo | -3,94 % | — |
Balance general
Activos totales
Responsabilidades totales
| (USD) | sept 2023info | Cambio interanual |
|---|---|---|
Efectivo y a corto plazo | 605,54 M | 95,64 % |
Activos totales | 822,10 M | 129,13 % |
Responsabilidades totales | 260,50 M | 44,09 % |
Patrimonio total | 561,60 M | — |
Acciones en circulación | 266,26 M | — |
Precio-valor contable | 127,25 | — |
Rentabilidad económica | 8,45 % | — |
Retorno sobre capital | 10,17 % | — |
Flujo de caja
Variación neta del flujo de caja
| (USD) | sept 2023info | Cambio interanual |
|---|---|---|
Ingresos netos | 30,75 M | 139,54 % |
Efectivo de operaciones | 2,77 M | 104,31 % |
Efectivo de inversión | -1,35 M | -124,92 % |
Efectivo de financiación | 32,13 M | 7.056,35 % |
Variación neta del flujo de caja | 33,55 M | 152,12 % |
Flujo de caja libre | -2,32 M | 91,72 % |
Información sobre la empresa
ImmunoGen, Inc. was a biotechnology company focused on the development of antibody-drug conjugate therapeutics for the treatment of cancer. ImmunoGen was founded in 1981 and was headquartered in Waltham, Massachusetts.
An ImmunoGen ADC contains a manufactured antibody that binds to a target found on cancer cells, with one of the company's potent cell-killing agents attached as a "payload". The antibody serves to deliver the cell-killing agent specifically to cancer cells bearing its target and the payload serves to kill these cells. In some cases, the antibody also has anticancer activity.
In November 2023, AbbVie, an American pharmaceutical company, announced it was buying ImmunoGen for $10.1 billion. Wikipedia
Director ejecutivo
Fundación
1981
Sitio web
Empleados
277
